FREDUNFredun Pharmaceuticals Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Fredun Pharmaceuticals Limited manufactures and sells pharmaceutical formulations, dietary/herbal supplements, nutraceuticals, animal healthcare products, cosmeceuticals, mobility and rehabilitation products, and other healthcare products in India, Africa, Southeast Asia, Commonwealth of Independent States countries, MENA region, and Latin America. The company offers allopathic formulations, including analgesics/NSAID, antacid/antiulcer, anthelmintic, antibacterial, anti-diabetic, anti-inflammatory, anti-malarial, anti-obesity, antacid, anthelmintic, anticoagulants, anticonvulsants, antidiarrhoeal, antidepressant, antifungal, antihistamines/antiallergic, antihypertensives, antiviral, bone modulating drugs, bronchodilators and anti-asthma drugs, calcium tablets, cardiovascular, diuretic, impotence drugs, laxative, and appetite stimulant with multivitamins. It also provides surgical products, such as IV fluids and cannulas, disposable syringes, infusion sets, surgical gloves and cottons, and personal healthcare products; APIs; direct compressible granules; pellets; animal healthcare products; aqua products; and niche products. Additionally, the company offers therapeutic products under the brand Hormone Range Products, a specialty therapeutics brand focused on longevity, hormone health, recovery science, and human performance solutions. Fredun Pharmaceuticals Limited was incorporated in 1987 and is headquartered in Mumbai, India.,
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on FREDUN — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Revenue growth: 90.7% YoY
- • Profit growth: 281.4% YoY
- • ROCE: 18.0%
- • Distance from 52-week high: 8.1% below high
- • Sector momentum: sector +6.2% (1m)
- • Max drawdown (1y): 10%
Bull case
- • Revenue growth: 90.7% YoY
- • Profit growth: 281.4% YoY
- • ROCE: 18.0%
- • Distance from 52-week high: 8.1% below high
Bear case
- • Recently listed — limited trading history, scores are provisional
- • Dividend yield: 0.00%
- • Insufficient price history
Key risks
- • Recently listed — limited trading history, scores are provisional
- • Dividend yield: 0.00%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹80.21). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.